Cargando…

A randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1 study to determine the safety, pharmacokinetics and food and faecal microbiome effects of ibezapolstat administered orally to healthy subjects

BACKGROUND: Clostridioides difficile infection is the most common cause of healthcare-associated infections in the USA, with limited treatment options. Ibezapolstat is a novel DNA polymerase IIIC inhibitor with in vitro activity against C. difficile. OBJECTIVES AND METHODS: Randomized, double-blind,...

Descripción completa

Detalles Bibliográficos
Autores principales: Garey, Kevin W, Begum, Khurshida, Lancaster, Chris, Gonzales-Luna, Anne, Bui, Dinh, Mercier, Julie, Seng Yue, Corinne, Ducharme, Murray P, Hu, Ming, Vince, Bradley, Silverman, Michael H, Alam, M Jahangir, Kankam, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7662179/
https://www.ncbi.nlm.nih.gov/pubmed/32892222
http://dx.doi.org/10.1093/jac/dkaa364